GSK Investigational Site
Panama City, Panama
NCT Number: NCT00653198
This study aims to estimate the effectiveness of Rotarix™ vaccine which is used nationwide as a part of the expanded program on immunization (EPI), in preventing RV SGE among hospitalised children born after 1 March 2006, which corresponds to the date of introduction of Rotarix™ in the national immunization program.
Looking for future studies?
Notify Me12 week and older
All sexes
Observational
Panama City, Panama
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for enrolled subjects and cases :
Inclusion criteria
for controls:
Exclusion criteria
for enrolled subjects and cases:
Exclusion criteria
for controls:
OR
GlaxoSmithKline
Industry
Hospital-based, Case-control Study to Assess the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 March 2006 and at Least 12 Weeks of Age, in Panama
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03954743
Infections, Infections, Rotavirus
Birmingham, Alabama, United States
View Trial DetailsNCT00353366
Digestive System Diseases, Gastroenteritis
Alabang, Muntinlupa City, Philippines
View Trial DetailsNCT00263666
Infections, Infections, Rotavirus
Attridgerville, Gauteng, South Africa
View Trial DetailsNCT02914184
Infections, Infections, Rotavirus
Birmingham, Alabama, United States
View Trial Details